Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings.
Troglitazone is an insulin-sensitizing agent used to treat type 2 diabetes mellitus. Several cases have been reported of troglitazone-induced hepatic injury; some requiring transplantation, others resulting in death. We here present a case of troglitazone-induced fulminant hepatic necrosis that led to the death of the patient.
Li
H
H
Department of Pathology and Laboratory Medicine, UMDNJ-New Jersey Medical School, UH/E141, 185 South Orange Avenue, Newark, NJ 07103, USA.
Heller
D S
DS
Leevy
C B
CB
Zierer
K G
KG
Klein
K M
KM
D000368:Aged; D001344:Autopsy; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D002839:Chromans / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017809:Fatal Outcome; D005913:Glipizide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008099:Liver / Q000473:pathology; D008297:Male; D013844:Thiazoles / Q000009:adverse effects*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone; D005913:Glipizide